Diabetes vaccine nears decisive trial – could enable early submission
Within the coming few months, Swedish biotech firm Diamyd Medical will receive intermediate phase trial data on an experimental vaccine against type 1 diabetes. A Danish doctor says the matter is "extremely interesting."
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN & IDA JACOBSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.